MYOV - Myovant Sciences hits 52-week high as observers see higher takeover offer
- Myovant Sciences ( NYSE: MYOV ) hit a 52-week high of of $25.52 on Tuesday as the biotech continues to benefit after rejecting a $2.4B buyout offer on Sunday.
- So far today, shares are up ~4% . This comes after Monday's massive 36% gain .
- Analysts say that Myovant's ( MYOV ) rejection of Sumitovant Biopharma's $22.75/share offer as a positive as it could signal a higher bid could be forthcoming .
- Seeking Alpha's Quant Rating views Myovant ( MYOV ) as a hold with high marks for momentum and growth .
For further details see:
Myovant Sciences hits 52-week high as observers see higher takeover offer